Wanbury launches nitrofurantoin sustained-release in India
This article was originally published in Scrip
Wanbury of India has launched nitrofurantoin 100mg sustained-release (marketed as Nitrofur SR) for the treatment of urinary tract infections (UTI) on the domestic market. The product, which is based on hydrophilic polymer matrix technology, offers a once-daily dosage. Currently, competing products fall in the instant-release category and need to be taken four times a day, often with side-effects such as gastrointestinal irritation and burning sensation, leading to poor patient compliance. The market for UTIs in India is estimated at about Rs12 billion ($247.3 million) and is growing at 14% per year. Wanbury is targeting sales of Rs100 million from Nitrofur SR in the first year. Wanbury, which was originally formed by the merger of Wander and Pearl Organics in India, is a manufacturer of metformin hydrochloride. Wander was originally a subsidiary of Sandoz, but the Indian founders took control of the company in 1995.
You may also be interested in...
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.